Organized by Lyonbiopole (Rhône-Alpes) and The Office for Science and Technology at the French Consulate in Los Angeles,

In partnership with the Salk Institute and French Bio Beach, La Jolla, (CA),

With the presence of Alsace Biovalley (Alsace), Cancer-Bio-Health Cluster (Toulouse), Orpheme (LR-PACA) and Medicen Paris Region,

With the support of the French Ministry of Industry (DGE). 

 

Télécharger le programme (PDF) 

 

Formulaire d'inscription

Program 

8.00 am Registration Opening

8.30 to 9.00 am Welcome Talks

• Roger Guillemin, Distinguished Professor, Nobel Prize of Medicine, President by interim of The Salk Institute for Biological Studies
• Philippe Larrieu, Consul General of France in Los Angeles

9.00 to 10.30 am Session 1: Key Issues for Vaccine Development - Part I

Chairman : Jean-Yves Bonnefoy, Ph.D., VP, R&D, Transgene 

• Keynote Speaker : Jacques Banchereau, Ph.D., Director, Baylor Institute for Immunology Research, Director, INSERM-U899, BIIR/ANRS/INSERM Center for Human Vaccines, Title:  Humanized mice to understand the pathophysiology of human dendritic cells in vivo
• Greg Lemke, Professor & Director, Molecular Neurobiology Laboratory, The Salk Institute for Biological Studies, Title: New Adjuvant Approaches,
• Anette Schneemann, Ph.D., Associate Professor, Department Molecular Biology, The Scripps Research Institute, Title: Virus-like particles as platforms for vaccine development
• Alain Rolland, Pharm.D., Ph.D., Senior Vice President, Product Development and Corporate Officer, Vical Inc., Title :  DNA Vaccines :  the end of the beginning

10.30 to 10.45 am Coffee break

10.45 to 11.45 am Session 1: Key Issues for Vaccine Development - Part II

Chairman : Jean-Yves Bonnefoy, Ph.D., VP, R&D, Transgene

• Marie Louise Michel, Ph.D., Department of Virology, Institut Pasteur, Director of Pathogenesis of hepatitis B virus laboratory, Title:  Therapeutic vaccination for chronic infection
• Phil Felgner, Professor, University of California at Irvine, Title: Profiling the Immune Response to Infections with Genome-Wide Proteome Arrays
• Philip R. Dormitzer,  M.D., Ph.D., Sr. Director, Viral Vaccine Research, Novartis Vaccines and Diagnostics, Title:  Structure based vaccine design

 

11.45 to 12.00 am Coffee break

 

12.00 to 1.00 pm Session 2: The Future of Therapeutic Monoclonals Antibodies

Chairman: Shane Crotty, Ph.D., Assistant Professor, Division of Vaccine Discovery, La Jolla Institute for Allergy and Immunology

• Ava Song, Ph.D., Scientist and Project Leader, Kirin Pharma USA, Inc., Shinichiro Kato, PhD, President and CSO, Kirin Pharma USA, Inc., Title: A fully human monoclonal antibody targeting influenza A virus M2 protein: Novel therapeutics for flu
  
• Jacques Descotes, M.D., Pharm.D., Ph.D., Professor, Claude Bernard University and Head, Lyon Poison Center, Title:  Immunotoxicity evaluation of monoclonal antibodies: from animal to man
   

1.00 to 2.30 pm Lunch - Posters Sessions

2.30 to 4.00 pm Session 3: Towards Humanized Animal Models

Chaiman : James P. Di Santo, M.D., Ph.D., Professor of Immunology, Institut Pasteur

• Amine Abina, M.D., Ph.D., President & CEO, Nokad, Title: Protein-functional-Knock-Out: a new approach in target validation and models of pathology
• Jérôme Tiollier, Ph.D., EVP Development & Operations, Innate Pharma, Title : Limits & Merits of preclinical pharmacological assessment of immunotherapeutic drugs during development
• Kader Thiam, Ph.D., VP Transgenic Technologies, genOway, Title :  Use of genetically modified animal models aiming at increasing the predictability and the throughput of immune response analysis in vivo
• Erwan Corcuff, Axenis Project Leader, Technical Coordinator of " Human Vaccine Consortium" and Medicen/Modexa/Biotherapies, Cytokines & Lymphoïd Development, Institut Pasteur, Title : Novel humanized mouse model for Testing HIV and HCV Vaccine Candidates

 

4.00 to 4.15 pm Coffee break

 

4.15 to 5.45 pm Session 4: New Perspectives for Antimicrobial Treatments

Chairman:  John A. T. Young, Ph.D., Professor and faculty Chair, The Salk Institute for Biological Studies

• Keynote Speaker : Jean-Pierre Gorvel, Ph.D., Director of the Centre d'Immunologie de Marseille-Luminy, Executive Director of the Foundation FINOVI, Innovation in Infectiology, Title:  Dr. Jekyll and Mr Hide : virulence factors as new antimicrobials
• Erica Ollmann Saphire, Ph.D.., Assistant Professor, Department of Immunology, The Scripps Research Institute, Title:  Crystal Structure of the Trimeric, Prefusion Ebola Virus Glycoprotein in Complex with a Neutralizing Antibody from a Human Survivor,
• Sonia Escaich, Ph.D., Vice-President, Chief Scientific Officer, Mutabilis SA, Title :  New antibacterial approaches using new targets
• Ludovic Tailleux, Ph.D., Mycobacterial Genetic Unit, Institut Pasteur, Title:  Challenges in Tuberculosis Therapies

 

5.45 to 6.15 pm Closing Session

 

6.15 to 7.00 pm Cocktail  and Posters sessions

 

 

Free of charge

 

For more information : Isabelle Scarabin Barbelet
International Development Director LYONBIOPOLE
17 rue Bourgelat
F - 69002 Lyon
Mob: + 33 (0)6 32 57 92 87
Tel: + 33 (0)4 72 40 79 75
Isabelle.scarabin@lyonbiopole.com 

 

 

Mireille Guyader, Ph.D
Attaché for Science & Technology

The Office of Science and Technology
French Consulate
10390 Santa Monica Blvd, suite 410
Los Angeles, CA 90025
Tel : (310) 235-3248
attache-sdv.mst@consulfrance-losangeles.org